Mirati Therapeutics reported $4.2M in Interest Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Alnylam Pharmaceuticals ALNY:US USD 7.82M 5.92M
BioCryst Pharmaceuticals BCRX:US USD 1.76M 1.15M
Bluebird Bio BLUE:US USD 383K 209K
Eli Lilly LLY:US USD 20.1M 9.9M
Exelixis EXEL:US USD 9.5M 4.74M
Moderna Inc MRNA:US USD 58M 18M
Nektar Therapeutics NKTR:US USD 2.05M 954K
Pfizer PFE:US USD 70M 40M
Puma Biotechnology PBYI:US USD 216K 151K
Sarepta Therapeutics SRPT:US USD 4.78M 2.37M
Ultragenyx Pharmaceutical RARE:US USD 3.48M 2.58M